Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting ...
Operator: Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference ...
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Investor's Business Daily on MSN
This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone
Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.
Travere reported Filspari net product sales up year-on-year, with contribution from its Tiopronin products. Learn why TVTX ...
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher ...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2026, and provided an operating forecast and business update. Ligand ...
Travere Therapeutics stock has delivered a very strong 341.0% return over the past five years, and the current valuation ...
(Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conf ...
Travere Therapeutics Inc. stock grades by Barron's. View TVTX fundamental and sentiment analysis powered by MarketGrader.
(SHOP) was up 25.3% in pre-market trading, and Travere Therapeutics Inc. (TVTX) was up 12.7%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results